using physician extenders

Information about using physician extenders

Published on May 8, 2008

Author: Melinda

Source: authorstream.com

Content

Using Physician Extenders to Create a CKD Clinic:  Using Physician Extenders to Create a CKD Clinic Theresa Becker, MSN, APNP Midwest Nephrology Assoc. Chronic Kidney Disease Clinic CKD Clinic:  CKD Clinic The ideas of: Linking CKD Clinics & Anemia Management Programs Using physician extenders in a multidisciplinary approach Are not new! CKD Clinic:  CKD Clinic ADEPT Clinic Arizonia Disease Education Prevention & Treatment Started as an anemia management clinic but soon developed into a CKD Clinic Patients are referred to the Vascular Access Program when GFRs are 25-30 mL/min. Curtis C, Yee B. The process of implementing a CKD Clinic Nephrology News & Issues. 2005;19:53-54. CKD Clinic:  CKD Clinic SHAPE UP Program Staging & Smoking Cessation Hypertension, Hyperglycemia, Hyperlipidemia, Hyperphosphatemia, Hyperparathyroidism, Hyperkalemia, & Hypervolemia Anemia Proteinuria Evaluation for KRT Undo nephrotoxins Preservation of veins & Patient education Gnanasekaran I, Kim S, Dimitrov V, Soni A. SHAPE UP-A management program for chronic kidney disease Dialysis & Transplantation. 2006;35: 294-302. CKD Clinic:  CKD Clinic One step further : A study by Curtis et al. suggested that even after appropriate & timely referral to a nephrologist, there is additional value of a multidisciplinary team approach in optimizing both short and long term patient outcomes. Curtis BM, Ravani P, Malberti F, et al. The short and long term impact of multi- disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant. 2005;20:147-154. CKD Clinic:  CKD Clinic Midwest Nephrology Associates CKD Clinic Model CKD Clinic:  CKD Clinic Components of the CKD Care Plan GFR < 60 ml/min. HTN Anemia Nutritional Status/DM Bone/Mineral Metabolism Neuropathy Functioning & Well-being Delaying Progression of CKD CKD Clinic:  CKD Clinic Components of the CKD Care Plan GFR < 30 ml/min. Review Modality Options Preparation for chosen option Transplant referral GFR < 15 ml/min. Tour Clinic Monitor for ESRD signs & symptoms CKD Clinic:  CKD Clinic CKD Patient Education Topics CKD and consequences; anemia and bone disease Common medications used in CKD Avoidance of nephrotoxic agents KRT Modalities Arm Preservation for HD access, Access placement & care of site Healthy living CKD Clinic:  CKD Clinic Access Teaching Pre AV access: Evaluation for appropriate arm such as vein mapping and instruction on saving that arm. Post AV access: Care of the site, exercising the access, and monitoring its development as well as instruction on its future use. CKD Clinic:  CKD Clinic Documentation Medication List Clinical Action Plan Health Maintenance Clinic Note Surgical Referral Form Vascular Access Record Chart Label CKD Clinic:  CKD Clinic Surgical Referral Form Date: __________________ Surgeon: __________________________ Phone: ______________ Fax: ________________ Patient: _________________________________________________ DOB: _______________ Nephrologist: ________________________ Phone: ______________ Fax: _______________ PCP: ______________________________ Phone: _______________ This patient is being referred to you for access placement. The desired access is an AV Fistula. In the event you are not planning to place an AV Fistula in this patient, please call the nephrologist prior to placing any other access. Patient’s non-dominant are is:  Right  Left Patient has been saving the following arm:  Right  Left Comments (ie: arm injury/mastectomy/pacemaker/previous access): Vein Mapping done pre-referral:  No  Yes – Date/Location: ______________________ Patient is currently on dialysis: Days: ____________________________________________________________________ Location/Phone: ____________________________________________________________ Patient is not on dialysis at this time: Anticipated hemodialysis start date: _______________________ months Most recent serum creatinine: ________ mg/dL & Creatinine Clearance/GFR: ________ ml/min Patient is on Anti-Coagulant Therapy:  No  Yes ___________________________________ Allergies:  NKDA  Yes _______________________________________________________ The following patient information is also enclosed:  Face Sheet  Vein Mapping Report  H & P  Recent Labwork  Medication List CKD Clinic:  CKD Clinic Vascular Access Record Stage 4 (GFR < 30 ml/min): Surgical consult should be for ‘AVF Only’. Instruct Patient to Preserve Veins of Non-Dominant or Appropriate Arm Obtain Vein Mapping KDOQI Benchmark: AVF placement of > 65% for prevalent patients. CKD Clinic:  CKD Clinic Surgeon ___________________ Date _______________ CKD Clinic:  CKD Clinic CKD Clinic:  CKD Clinic Chart Label CKD Clinic:  CKD Clinic AVF Statistics Patients Initiating HD 1/1/06 to 10/31/06 CKD Clinic:  CKD Clinic Vaccination Statistics 7/1/06 to 12/31/06 CKD Insurance Issues:  CKD Insurance Issues CPT Office Visit Billing Codes Low complexity visit (~ 15 min.) – 99213 Moderate complexity visit (~ 25 min.) – 99214 High complexity visit (~ 40 min.) – 99215 CKD Insurance Issues:  CKD Insurance Issues ICD 9 Office Visit Billing Codes CKD Stage 1 (GFR > 90) – 585.1 CKD Stage 2 (GFR 60-89) – 585.2 CKD Stage 3 (GFR 30-59) – 585.3 CKD Stage 4 (GFR 15-29) – 585.4 CKD Stage 5 (GFR<15) – 585.5 CKD Insurance Issues:  CKD Insurance Issues Office Visit Reimbursement Commercial Insurances reimburse NPs at 100% of MD charges Medicare only reimburses NPs at 80% of MD charges Medicare and a secondary insurance reimburses NPs at 100% of MD charges Anemia Management Program :  Anemia Management Program Erythropoietin Stimulating Agents (ESA) Available for Stage 1 – 5 CKD Patients McClellan, Schoolwerth A., Gehr, T. Clinical Management of Chronic Kidney Disease. Cadido, OK: Professional Communications, Inc.; 2006:185-208. ESA Agents:  ESA Agents Aranesp Package Insert Amgen® ESA Agents:  ESA Agents Side Effect Profile HTN and Headaches Myalgias Diarrhea Contraindications Uncontrolled HTN Known hypersensitivity to the active substance or any of the excipients ESA Agents:  ESA Agents FDA Black Box Warning Issued 3/9/07 Use the lowest dose of ESA that will gradually increase the Hgb concentration to the lowest level sufficient to avoid the need for RBC transfusion. ESAs increase the risk for death and serious CV events when administered to target a Hgb > 12 gm/dL. ESA Agents:  ESA Agents RPA Renal Physicians Association Risks and benefits must be on individual patient basis Evidence based Hgb targets are helpful and should be reintroduced May lead to unacceptably low Hgb levels AAKP American Association of Kidney Patients Warning may be confusing to patients & providers Supports targeting Hgbs between 11 and 12 Lower Hgb lead to concerns regarding QOL ESA Agents:  ESA Agents Epoetin alfa (Procrit) Single-Dose Preservative Free Vials 2,000 units, 3,000 units, 4,000 units, 10,000 units, 40,000 units/1 mL Multi-Dose Preserved Vials 20,000 units/1 mL 20,000 units/2 mL ESA Agents:  ESA Agents Darbepoetin alfa (Aranesp) Single-Dose Preservative Free Vials 25 mcg, 40 mcg, 60 mcg, 100 mcg, 200 mcg, 300 mcg, 500 mcg/1 mL 150 mcg/0.75 mL ESA Agents:  ESA Agents Darbepoetin alfa (Aranesp) Single-Dose Prefilled Syringes 25 mcg/0.42 mL 40 mcg/0.4 mL 60 mcg/0.3 mL 100 mcg/0.5 mL 150 mcg/0.3 mL 200 mcg/0.4 mL SingleJect Syringe SureClick Syringe ESA Utilization Guidelines:  ESA Utilization Guidelines Hgb Level of < 11.0 gm/dL within 30 days T. Sat. and/or Ferritin within 30 to 90 days Serum creatinine within 30 days Patient’s weight in kilograms ESA Dose per kilogram Erythropoietin level is NOT recommended ESA Utilization Guidelines:  ESA Utilization Guidelines Target Hgb at or above 11.0 gm/dL Caution when intentionally maintaining Hgb > 13.0 gm/dL Monitor Hgb minimum of every 30 days Target Ferritin > 100 ng/mL and T. Saturation > 20% Monitor Iron Indices Quarterly ESA Utilization Guidelines:  ESA Utilization Guidelines Dose Adjustments If Hgb increases by > 2 gm/dL per 4 weeks and/or Hgb level > 12 gm/dL, decrease dose by 20 to 25% If Hgb level is increasing < 1 gm/dL per 4 weeks, increase dose by 20 to 25% ESA Utilization Guidelines:  ESA Utilization Guidelines Dose Adjustments 20 to 25% dose adjustments may be achieved by: Altering the ESA dose Altering the time interval between injections ESA Utilization Guidelines:  ESA Utilization Guidelines Dose Adjustments Increases in dose should not be made more frequently than once a month. Avoid holding doses to avoid marked drop in ESA sensitive RBC precursors and the ‘seesaw’ effect of Hgb poor response pattern. ESA Utilization Guidelines:  ESA Utilization Guidelines Dose Adjustments More frequent Hgb &/or iron indices monitoring may be necessary when: Recent bleeding or surgery Post hospitalization Post IV iron course Periods of ESA hypo-response ESA Utilization Guidelines:  ESA Utilization Guidelines ESA Resistance Infection/Inflammation Blood Loss, Guiac Positive Stools Hyperparathyroidism B12, Folate Deficiencies Sickle cell, Thalacemias Multiple Myeloma/Malignancy ACE Inhibitor Use ESA Utilization Guidelines:  ESA Utilization Guidelines Dose Adjustments Recent data indicates Hgb levels can be maintained with every two week epoetin alfa dosing and monthly darbepoetin alfa dosing. Benefits include increased staff productivity and patient satisfaction/compliance. Moore T., Chookie S. Extended dosing od darbepoetin alfa in patients with chronic kidney disease not on dialysis: A review of recent data. Journal of ANNA 2005;32:399-407. ESA Utilization Guidelines:  ESA Utilization Guidelines Medicare considers doses exceeding 90,000 units per week for epoetin alfa or 200 mcg per week for darbepoetin alfa to be rarely reasonable and necessary. Medical justification for doses exceeding these amounts should be documented in the patient’s record. ESA Utilization Guidelines:  ESA Utilization Guidelines ESA Flowsheet Hemoglobin Monitoring :  Hemoglobin Monitoring HemoCue vs. Lab Draw HemoCue Analyzer utilizes an optical measuring microcuvette. It provides nearly instantaneous Hgb results with very good accuracy. Traditional Lab Draw may be used. However, it will require another appointment or extended patient visit while awaiting lab results. Hemoglobin Monitoring:  Hemoglobin Monitoring HemoCue Analyzer HemoCue Inc. 40 Empire Drive Lake Forest, CA 92630 Phone: 1800.881.1611 Fax: 1800.333.7043 www.hemocue.com HemoCue machines require a CLIA (Clinical Laboratory Improvement Amendment) Certificate of Waiver www.cms.hhs.gov/clia/ ESA Insurance Issues:  ESA Insurance Issues CPT ESA Billing Codes Epoetin alfa – J0885 (Standard unit 1,000 units) Darbepoetin alfa - J0881 (Standard unit 1 mcg) Injection – 90772 HemoCue Lab – 85018QW ESA Insurance Issues:  ESA Insurance Issues ICD 9 ESA Billing Codes Anemia – 285.9 CKD Stage 1 (GFR > 90) – 585.1 CKD Stage 2 (GFR 60-89) – 585.2 CKD Stage 3 (GFR 30-59) – 585.3 CKD Stage 4 (GFR 15-29) – 585.4 CKD Stage 5 (GFR<15) – 585.5 ESA Insurance Issues:  ESA Insurance Issues Benefit Determination Billing Office Review of Patient’s Insurance Procit – PROCRITline 1800.553.3851 or www.procritline.com Aranesp – Amgen Reimbursement Connection 1800.272.9376 or www.reimbursementconnection.com ESA Insurance Issues:  ESA Insurance Issues Benefit Assistance HealthWell Foundation P.O. Box 4133 Gaithersburg, MD 20885-4133 Phone: 1800.675.8416 Fax: 1800.282.7692 www.healthwellfoundation.org ESA Insurance Issues:  ESA Insurance Issues Drug Assistance Drug company vouchers which generally allow one month supply of ESA ESA samples may be available ESA Self Administration:  ESA Self Administration Initial Teaching ESA script must include Anemia & CKD Stage ICD 9 codes Instruct patient on storage, handling, and observe administration of ESA Office visit charge ESA Self Administration:  ESA Self Administration Monitoring Monthly HemoCue lab charge vs. traditional lab draw Office visit charge New Agents:  New Agents Mircera Developed by Roche First and only Continuous Erythropoietin Receptor Activator (C.E.R.A.) Twice monthly dosing schedule, however generally will be able to administer monthly yet maintain stable Hgb levels IV/SC administration May be used in CKD & dialysis patients IV Iron:  IV Iron Iron Sucrose (Venofer) 100 mg/1 mL vial Administer 200 mg slow IV infusion over 2 to 5 minutes on 5 different occasions within a 14 day period. Typically dosed weekly for 5 weeks. Generally administered when Ferritin < 100 ng/mL and/or T. Saturation < 20% IV Iron Insurance Issues:  IV Iron Insurance Issues CPT Iron Billing Code Iron Sucrose – J1786 (Standard unit 1 mg) IV Infusion – 90765 Office charge, high complexity visit - 99215 ICD 9 Iron Billing Code Iron Deficiency Anemia – 280.9 Questions:  Questions

Related presentations


Other presentations created by Melinda

MOLLUSCA Power Point
20. 02. 2008
0 views

MOLLUSCA Power Point

Consumer s Rights
07. 05. 2008
0 views

Consumer s Rights

spscicomp6
02. 05. 2008
0 views

spscicomp6

Energy1
02. 05. 2008
0 views

Energy1

FML2004 1
02. 05. 2008
0 views

FML2004 1

Roberta Zobbi
02. 05. 2008
0 views

Roberta Zobbi

Brain Cancer Causes
02. 05. 2008
0 views

Brain Cancer Causes

Anes Equip Probs 03
30. 04. 2008
0 views

Anes Equip Probs 03

Fin525Fall2006Week7
28. 04. 2008
0 views

Fin525Fall2006Week7

Keynote
22. 04. 2008
0 views

Keynote

Bonding
16. 02. 2008
0 views

Bonding

Systems Analysis Presentation
06. 03. 2008
0 views

Systems Analysis Presentation

BizRetPresentation Final
01. 10. 2007
0 views

BizRetPresentation Final

9 Oyieke Illicit Trade
10. 10. 2007
0 views

9 Oyieke Illicit Trade

Khosla Biofuels GEC DC 3 1 06
15. 10. 2007
0 views

Khosla Biofuels GEC DC 3 1 06

28 Thermal Baths at Vals
19. 10. 2007
0 views

28 Thermal Baths at Vals

pk momterrey 11 04
21. 10. 2007
0 views

pk momterrey 11 04

marie robinson
22. 10. 2007
0 views

marie robinson

OceanStore tahoe2
07. 10. 2007
0 views

OceanStore tahoe2

gis in health
23. 10. 2007
0 views

gis in health

Spalart SanFran 06
30. 10. 2007
0 views

Spalart SanFran 06

W Simpson Foresman
02. 11. 2007
0 views

W Simpson Foresman

transitioning
07. 11. 2007
0 views

transitioning

Lopez Cerezo y Lujan
22. 10. 2007
0 views

Lopez Cerezo y Lujan

024
25. 10. 2007
0 views

024

qiao
15. 11. 2007
0 views

qiao

Skills for Life2
19. 11. 2007
0 views

Skills for Life2

Dr Painter Food Psychology
22. 10. 2007
0 views

Dr Painter Food Psychology

MIE2006 RIDE
29. 10. 2007
0 views

MIE2006 RIDE

thesaurus 1
04. 12. 2007
0 views

thesaurus 1

burns pp
04. 01. 2008
0 views

burns pp

rubrics
01. 01. 2008
0 views

rubrics

IZ 101 Slides Revision
30. 10. 2007
0 views

IZ 101 Slides Revision

midterm review
02. 11. 2007
0 views

midterm review

Armstrong
03. 01. 2008
0 views

Armstrong

Mr KONDO Presentation 070603
09. 10. 2007
0 views

Mr KONDO Presentation 070603

dossier de presse
24. 10. 2007
0 views

dossier de presse

pres clarkm5
15. 10. 2007
0 views

pres clarkm5

Joe Caddell ppt
24. 10. 2007
0 views

Joe Caddell ppt

Slivovsky CPE350 Lecture1
31. 12. 2007
0 views

Slivovsky CPE350 Lecture1

materiasprimas
04. 10. 2007
0 views

materiasprimas

swords
26. 02. 2008
0 views

swords

capstone designing
31. 10. 2007
0 views

capstone designing

03 Basic Chemistry
04. 03. 2008
0 views

03 Basic Chemistry

Contraception
12. 10. 2007
0 views

Contraception

P Letardi
01. 11. 2007
0 views

P Letardi

NUR lecture 2
07. 01. 2008
0 views

NUR lecture 2

Global Health
11. 03. 2008
0 views

Global Health

Solar5
07. 04. 2008
0 views

Solar5

Gumbert vormittags
29. 12. 2007
0 views

Gumbert vormittags

35
22. 10. 2007
0 views

35

STB OrgChart 050819
25. 03. 2008
0 views

STB OrgChart 050819

wf conf june5
09. 04. 2008
0 views

wf conf june5

global nondeal roadshow
11. 04. 2008
0 views

global nondeal roadshow

L04 dg c2
10. 12. 2007
0 views

L04 dg c2

20 Non renewables
16. 04. 2008
0 views

20 Non renewables

SAINSEL Kickoff
23. 10. 2007
0 views

SAINSEL Kickoff

Futures Pricing and Strategies
17. 04. 2008
0 views

Futures Pricing and Strategies

tutorial avedon
24. 02. 2008
0 views

tutorial avedon

k waldron avnwx tdas
07. 03. 2008
0 views

k waldron avnwx tdas

ASPO2005 Leonard
12. 10. 2007
0 views

ASPO2005 Leonard

powerpointmba
16. 11. 2007
0 views

powerpointmba

marxfam2
19. 02. 2008
0 views

marxfam2

antihistamines 2006
16. 10. 2007
0 views

antihistamines 2006

CD San Francisco 11 14
29. 10. 2007
0 views

CD San Francisco 11 14

russian transportation
11. 10. 2007
0 views

russian transportation

ibcoldwar
08. 04. 2008
0 views

ibcoldwar

Agrimi Workshop7 THC5
17. 10. 2007
0 views

Agrimi Workshop7 THC5

Pompey the Great
03. 04. 2008
0 views

Pompey the Great

wipo smes sin 07 8 parta
28. 02. 2008
0 views

wipo smes sin 07 8 parta

P1Slides
17. 10. 2007
0 views

P1Slides

JubbDinner Keynote
07. 01. 2008
0 views

JubbDinner Keynote

old china new japan
09. 10. 2007
0 views

old china new japan

Paul Browne Selected MSc Work
29. 09. 2007
0 views

Paul Browne Selected MSc Work

ppt simons
13. 11. 2007
0 views

ppt simons

Bucharest Denisov
11. 10. 2007
0 views

Bucharest Denisov

Huettner QA systems 00 04 11
16. 10. 2007
0 views

Huettner QA systems 00 04 11

4941
13. 04. 2008
0 views

4941

Lucy
05. 01. 2008
0 views

Lucy